[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612716":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":43,"responsibleParty":62,"collaborators":26,"id":67,"slug":26,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":26,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Montreal Heart Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ticagrelor monotherapy","EXPERIMENTAL","Ticagrelor 90 mg orally twice daily + placebo orally once daily",[13],"Drug: Ticagrelor + placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"DAPT with ticagrelor and aspirin","ACTIVE_COMPARATOR","Ticagrelor 90 mg orally twice daily + aspirin 80 mg orally once daily",[19],"Drug: Ticagrelor + aspirin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ticagrelor + placebo","Ticagrelor 90 mg twice daily + placebo once daily",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Ticagrelor + aspirin","Ticagrelor 90 mg twice daily + aspirin 80 mg once daily",[15],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Guillaume Marquis-Gravel, MD","CONTACT","1-514-376-3330","2777","guillaume.marquis.gravel@umontreal.ca",{"name":39,"role":34,"phone":40,"phoneExt":41,"email":42},"Roseline Therrien","1-514-461-1300","2007","roseline.therrien@seriant.org",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Montreal","Quebec","H1Y2P3","Canada",{"type":51,"coordinates":52},"Point",[53,54],-73.58781,45.50884,{"lat":54,"lon":53},[57,58],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},{"name":59,"role":34,"phone":35,"phoneExt":60,"email":61},"Samara Bloom, Msc","2698","samara.bloom@icm-mhi.org",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":66,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Guillaume Marquis-Gravel","Associate professor of clinic","Université de Montréal","100612716",false,"NCT07257198","Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)","PANTHEON","Inclusion criteria:\n\n* Age ≥18 years;\n* Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;\n* Coronary angiogram performed;\n* Planned for medical management alone, without revascularization;\n* Willingness to participate and to attend study visits;\n* Expected life expectancy ≥12 months.\n\nExclusion criteria:\n\n* Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;\n* Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;\n* Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);\n* Confirmed or suspected spontaneous coronary artery dissection;\n* Concomitant indication for chronic oral anticoagulant;\n* Concomitant non-coronary indication for dual antiplatelet therapy;\n* Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;\n* Previous hospitalization for MI, PCI, or CABG within 12 months;\n* Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;\n* Unsuitability for either randomization treatment, based on the judgement of the treating physician","ALL","18 Years",{"count":77,"type":78},2570,"ESTIMATED","INTERVENTIONAL",[81],"PHASE3","In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.",[84,85,86],"NSTEMI - Non-ST Segment Elevation MI","STEMI (ST Elevation MI)","Myocardial Infarction",[88,89,90,91,92,93,94,95,96,97,98],"Dual antiplatelet therapy","NSTEMI","medical treatment","STEMI","aspirin","ticagrelor","bleeding","ischemic events","randomized trial","pragmatic trial","randomized controlled trial","2026-03-08",{"date":101,"type":102},"2026-03-10","ACTUAL",{"date":104,"type":102},"2026-03-03",{"date":106,"type":78},"2031-01-01",{"name":5,"class":6},1]